PROTEGO BIOPHARMA, INC.
Diagnostic biomarker assay for detecting non-native transthyretin (NNTTR) aggregates in blood for early ATTR amyloidosis diagnosis
- Sector
- Medtech
- Headquarters
- San Diego, CA
- Latest Form D
- $32.9M, Dec 2025
- Total capital
- $88M
- Federal grants
- $3M
- 4 awards · 2018–2021
- Rank in peer group#80 of 112
- Private capital raised
- $85M
- 3 Form D · last Dec 2025
- 11 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 40 pending
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 3rd filing$32.9M
- Private capital raisedForm D · SEC · 2nd filing$51M
- Federal grantHealth and Human S · Phase II · Analytical Validation of Non-native Transthyretin (NNTTR) As A Candidate Biomarker for Transthyretin Amyloidoses (ATTR)$2.1M
- Federal grantHealth and Human S · Phase I · Development of An Oral, Brain/Eye penetrating, Second Generation TTR Stabilizer for The Treatment of Transthyretin Amyloidoses$210K
- Private capital raisedForm D · SEC · 1st filing$1M
- Federal grantHealth and Human S · Phase I · Development of An Oral, Brain/Eye penetrating, Second Generation TTR Stabilizer for The Treatment of Transthyretin Amyloidoses$419K
- Federal grantHealth and Human S · Phase I · Development of an early diagnostic and biomarker of treatment response for TTR amyloidoses (ATTR)$325K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
22months
from PROTEGO BIOPHARMA, INC.’s first federal award to its first private round.
- First federal award · Mar 2018
- Health and Human S · $325K
- First Form D · Dec 2019
- $1M · 1st Form D
- Awards before first raise
- 2 awards
An association in public records, not a cause or a prediction.
Standing among 112 peers
Line = medianMedtech · Instrument
- Federal grantsBelow median
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Richard LabaudiniereResearcherDirectorLinked by $629K in grants as PI
- XIN JIANGResearcherExecutive OfficerLinked by $2.4M in grants as PI
- Brent J. WarnerExecutive Officer, DirectorNamed in SEC Form D filings
- Brent J. WarnerExecutive Officer, DirectorNamed in SEC Form D filings
- Edward HurwitzDirectorNamed in SEC Form D filings
- HANK MICHAEL PETRASSIExecutive OfficerNamed in SEC Form D filings
Show all 15 people
- HANK MICHAEL PETRASSIExecutive OfficerNamed in SEC Form D filings
- Helen KimDirectorNamed in SEC Form D filings
- JANWILLEM NAESENSDirectorNamed in SEC Form D filings
- JEFFERY KELLYDirectorNamed in SEC Form D filings
- Jeffrey KellyDirectorNamed in SEC Form D filings
- LAURA BRASSDirectorNamed in SEC Form D filings
- SAOUSSEN BEN HALIMADirectorNamed in SEC Form D filings
- SHELLEY CHUDirectorNamed in SEC Form D filings
- TIM LOHOFFDirectorNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 40- PendingLinear Heteroaryl Diamide IRE1/XBP1S ActivatorsUSPTOApplication 19134142
- PendingCyclic Pyrazole Diamide IRE1/XBP1S ActivatorsUSPTOApplication 19134167
- PendingCompounds For Treating Light Chain AmyloidosisUSPTOApplication 19239698
Show all 40 patent records
- Linear Heteroaryl Diamide IRE1/XBP1S ActivatorsJul 9, 2026 · Application 19134142Pending
- Cyclic Pyrazole Diamide IRE1/XBP1S ActivatorsJul 9, 2026 · Application 19134167Pending
- Compounds For Treating Light Chain AmyloidosisDec 18, 2025 · Application 19239698Pending
- Acoramidis Analogs For Stabilizing Transthyretin And Inhibiting Transthyretin MisfoldingJun 20, 2024 · Application 18419303Pending
- Transthyretin Stabilizing CompoundsJun 13, 2024 · Application 18419081Pending
- Spirocycle Containing Bicyclic Heteroaryl CompoundsMay 30, 2024 · Application 18494596Pending
- Spirocycle Containing Pyridine CompoundsMay 30, 2024 · Application 18494601Pending
- Spirocycle Containing Pyridone CompoundsMay 30, 2024 · Application 18494587Pending
- Spirocyclic Imidazolidinones And Imidazolidinediones For Treatment Of Light Chain AmyloidosisFeb 15, 2024 · Application 18485010Pending
- Compounds, Compositions And Methods For Stabilizing Transthyretin And Inhibiting Transthyretin MisfoldingSep 14, 2023 · Application 17759265Pending
- Linear Heteroaryl Diamide IRE1/XBP1S ActivatorsApplication PCTUS2023081633Pending
- Sequence-independent Quantification Of Proteolytically Unstable Plasma Lambda Free Light Chain Protein For Al Amyloidosis DiagnosisApplication 63594556Pending
- Spirocycle Containing Pyridine CompoundsApplication PCTUS2023077786Pending
- Spirocycle Containing Bicyclic Heteroaryl CompoundsApplication PCTUS2023077783Pending
- Spirocycle Containing Pyridone CompoundsApplication PCTUS2023077778Pending
- Sequence-independent Quantification Of Proteolytically Unstable Plasma Lambda Free Light Chain Protein For Al Amyloidosis DiagnosisApplication 63486587Pending
- CYCLIC HETEROARYL DIAMIDE IRE1/XBP1s ACTIVATORSApplication 63385548Pending
- LINEAR HETEROARYL DIAMIDE IRE1/XBP1s ACTIVATORSApplication 63385543Pending
- Spirocycle Containing Amidopyridine CompoundsApplication 63381051Pending
- Spirocycle Containing Bicyclic Heteroaryl CompoundsApplication 63381034Pending
- Spirocycle Containing Pyridone CompoundsApplication 63381010Pending
- Transthyretin Stabilizing CompoundsApplication PCTUS2022038460Pending
- Acoramidis Analogs For Stabilizing Transthyretin And Inhibiting Transthyretin MisfoldingApplication PCTUS2022038506Pending
- Spirocyclic Imidazolidinones And Imidazolidinediones For Treatment Of Light Chain AmyloidosisApplication PCTUS2022025725Pending
- Acoramidis Analogs For Stabilizing Transthyretin And Inhibiting Transthyretin MisfoldingApplication 63203685Pending
- Transthyretin Stabilizing CompoundsApplication 63203691Pending
- HETEROARYL DIAMIDE IRE1/XBP1s ACTIVATORSApplication 63202118Pending
- Spirocyclic Imidazolidinediones For Treatment Of Light Chain AmyloidosisApplication 63201288Pending
- Spirocyclic Imidazolidinones For Treatment Of Light Chain AmyloidosisApplication 63201291Pending
- Compounds, Compositions And Methods For Stabilizing Transthyretin And Inhibiting Transthyretin MisfoldingApplication PCTUS2021015271Pending
- Compounds, Compositions And Methods For Stabilizing Transthyretin And Inhibiting Transthyretin MisfoldingApplication 63009241Pending
- Methods And Reagents For Light Chain Amyloidosis DiagnosisApplication PCTUS2025043243Pending
- Compounds, Compositions And Methods For Stabilizing Transthyretin And Inhibiting Transthyretin MisfoldingApplication 62966978Pending
- Tetrahydrofuranyl IRE1/XBP1S ActivatorsApplication PCTUS2025032437Pending
- Bicyclic And Heterocyclic Amide CompoundsApplication PCTUS2025027325Pending
- Method Of Light Chain Amyloidosis DiagnosisApplication 63688766Pending
- Reagents, Methods, And Kits For Limited Proteolysis Assisted Immune-quantification Of Proteolytically Unstable Plasma Lambda Free Light Chain Protein For Diagnosis And TreatmentApplication 63686444Pending
- Compounds for Treating Light Chain AmyloidosisApplication 63660919Pending
- TETRAHYDROFURANYL IRE1/XBP1s ACTIVATORSApplication 63656363Pending
- Method Of Sequence-independent Quantification Of Proteolytically Unstable Plasma Lambda Free Light Chain Protein For Al Amyloidosis DiagnosisApplication PCTUS2024016721Pending
Related companies, and why
- LC ACQUISITION LLCSimilar federal contract value in Medtech · null in contracts
- DEEP REASONING AI INCSimilar federal contract value in Medtech · null in contracts
- NEURALYNX, INC.Similar federal contract value in Medtech · null in contracts
- ARGUS COGNITIVE, INC.Similar federal contract value in Medtech · null in contracts
- Cernostics IncSimilar federal contract value in Medtech · null in contracts
- SPEECHVIVE, INC.Similar federal contract value in Medtech · null in contracts
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .